Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

Ghisoli M, Rutledge M, Stephens PJ, Mennel R, Barve M, Manley M, Oliai BR, Murphy KM, Manning L, Gutierrez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J.

J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822.

PMID:
28338569
2.

Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, Pappen BO, Whiting S, Rao D, Senzer N, Nemunaitis J.

Mol Ther. 2016 Aug;24(8):1478-83. doi: 10.1038/mt.2016.86. Epub 2016 Apr 25.

3.

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Ghisoli M, Barve M, Schneider R, Mennel R, Lenarsky C, Wallraven G, Pappen BO, LaNoue J, Kumar P, Nemunaitis D, Roth A, Nemunaitis J, Whiting S, Senzer N, Fletcher FA, Nemunaitis J.

Mol Ther. 2015 Jun;23(6):1103-1109. doi: 10.1038/mt.2015.43. Epub 2015 Mar 19.

4.
5.

Primary cutaneous angiosarcoma of the breast after breast trauma.

Cao Y, Panos L, Graham RL, Parker TH 3rd, Mennel R.

Proc (Bayl Univ Med Cent). 2012 Jan;25(1):70-2.

6.

Primary cutaneous large B-cell lymphoma, leg type.

Thomas V, Dobson R, Mennel R.

Proc (Bayl Univ Med Cent). 2011 Oct;24(4):350-3.

7.

Pigmented villonodular synovitis responsive to imatinib therapy.

Snoots WM, Watkins D, Dockery D, Mennel R, Cheek BS.

Proc (Bayl Univ Med Cent). 2011 Apr;24(2):134-8. No abstract available.

8.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology.

J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. Review.

PMID:
17954709
9.

Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.

Nemunaitis J, Cunningham C, Senzer N, Gray M, Oldham F, Pippen J, Mennel R, Eisenfeld A.

Cancer Invest. 2005;23(8):671-6.

PMID:
16377585
10.

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM.

J Clin Oncol. 2005 Aug 20;23(24):5542-51.

PMID:
16110015
11.

ACCO: ASCO core curriculum outline.

Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J; American Society of Clinical Oncology.

J Clin Oncol. 2005 Mar 20;23(9):2049-77. Epub 2005 Feb 22. No abstract available.

PMID:
15728218
12.

Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.

Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, Grove W, Olson S.

Cancer J. 2003 Jan-Feb;9(1):58-66.

PMID:
12602769
13.

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.

Jones SE, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, Blum J, Kirby R, Stone M, Pippen J, George T, Orr D, Knox S, Grant M, Peters G, Savino D, Rietz C.

Clin Breast Cancer. 2002 Jun;3(2):147-52.

PMID:
12123539
14.

Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.

Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R, Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D, Rietz C.

Clin Breast Cancer. 2001 Jan;1(4):310-4; discussion 315-7.

PMID:
11899353
15.

Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.

Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M.

J Clin Oncol. 1999 Oct;17(10):3025-32.

PMID:
10506596
16.

A phase II study of piritrexim in patients with advanced squamous head and neck cancer.

Uen WC, Huang AT, Mennel R, Jones SE, Spaulding MB, Killion K, Havlin K, Keegan P, Clendeninn NJ.

Cancer. 1992 Feb 15;69(4):1008-11.

PMID:
1735068

Supplemental Content

Loading ...
Support Center